Skip to main content

WHO approves Mylan generic HIV drugs for use in developing world


PITTSBURGH — The World Health Organization has approved three generic second-line treatments for HIV made by Mylan, the drug maker said Tuesday. The drugs will be delivered to people in developing countries living with HIV and AIDS.

Subsidiary Mylan Labs won approval for atazanavir capsules in the 300-mg strength and ritonavir tablets in the 100-mg strength with tenofovir disoproxil fumarate and lamivudine tablets in the 300-mg/300-mg strength; a fixed-dose combination of atazanavir sulfate and ritonavir tablets in the 300-mg/100-mg strength; and a fixed-dose combination tablet of abacavir sulfate, lamivudine and zidovudine in the 300-mg/150-mg/300-mg strength.

Atazanavir, ritonavir, tenofovir disoproxil fumarate and lamivudine are generic versions of Bristol-Myers Squibb's Reyataz, Abbott Labs' Norvir, Gilead Sciences Viread and GlaxoSmithKline's Epivir, respectively.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

This ad will auto-close in 10 seconds